Filip De Keyser

14.0k total citations
237 papers, 9.3k citations indexed

About

Filip De Keyser is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Filip De Keyser has authored 237 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Rheumatology, 58 papers in Immunology and 50 papers in Pathology and Forensic Medicine. Recurrent topics in Filip De Keyser's work include Rheumatoid Arthritis Research and Therapies (98 papers), Systemic Lupus Erythematosus Research (63 papers) and Spondyloarthritis Studies and Treatments (57 papers). Filip De Keyser is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (98 papers), Systemic Lupus Erythematosus Research (63 papers) and Spondyloarthritis Studies and Treatments (57 papers). Filip De Keyser collaborates with scholars based in Belgium, Netherlands and Germany. Filip De Keyser's co-authors include Eric Veys, Dominique Baeten, Elli Kruithof, Herman Mielants, Filip Van den Bosch, Dirk Elewaut, Vanessa Smith, Leen De Rycke, Saskia Decuman and Ilse Hoffman and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Gastroenterology.

In The Last Decade

Filip De Keyser

232 papers receiving 9.0k citations

Peers

Filip De Keyser
Comparison fields: 5 of 149
  • Rheumatology 5.2k
  • Immunology 3.1k
  • Pathology and Forensic Medicine 1.9k
  • Hematology 1.5k
  • Molecular Biology 1.4k
Replace Athanasios G. Tzioufas with:
Athanasios G. Tzioufas Greece
Carlomaurizio Montecucco Italy
Gerd‐Rüdiger Burmester Germany
Neil McHugh United Kingdom
Panayiotis G. Vlachoyiannopoulos Greece
Xavier Mariette France
Tore Saxne Sweden
Jacob M. van Laar Netherlands
Joachim R. Kalden Germany
Falk Hiepe Germany
Athanasios G. Tzioufas Greece View profile →
Citations per field, relative to Filip De Keyser
Filip De Keyser · 1×
Citations per year, relative to Filip De Keyser
Filip De Keyser · 1×

Countries citing papers authored by Filip De Keyser

Since Specialization
Citations

This map shows the geographic impact of Filip De Keyser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip De Keyser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip De Keyser more than expected).

Fields of papers citing papers by Filip De Keyser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip De Keyser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip De Keyser. The network helps show where Filip De Keyser may publish in the future.

Co-authorship network of co-authors of Filip De Keyser

This figure shows the co-authorship network connecting the top 25 collaborators of Filip De Keyser. A scholar is included among the top collaborators of Filip De Keyser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip De Keyser. Filip De Keyser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1 1
2 6
3
Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
6
4
A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate
1
5
Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a bi-centre study
2
6
Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition.
1
7
Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect
1
8
S100A12-expression is upregulated by TNF and may serve as a marker for the success of anti-TNF therapy
1
9
Bowel inflammation in rheumatic diseases: Trigger or consequence
1
10
Comparing statistics with machine learning models to predict dose increase of infliximab for rheumatoid arthritis patients
1
11
Increased systemic and local expression of toll-like receptor 2 and 4 in spondyloarthropathy is downmodulated by tumour necrosis factor alpha blockade
4
12
IgM anti-dsDNA autoantibodies are the main antinuclear reactivity induced by infliximab but not etanercept treatment in vivo: Biological and clinical implications
3
13
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase are pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity
1
14
Preliminary evidence for a retardation of structural damage in patients with ankylosing spondylitis continuously treated with infliximab for 4 years
1
15
Comparison of Machine Learning models for prediction of dose increase in patients with rheumatoid arthritis
3
16 1
17
Rheumatoid factor and anti-citrullinated peptide antibodies in rheumatoid arthritis: Diagnostic value and association with radiological progression
1
18
Is expression of intracellular citrullinated proteins in synovial tissue specific for rheumatoid arthritis? Comment on the article by Baeten et al - Reply.
2
19
The presentation of the immunodominant epitope of HC gp-39 in the context of the RA-associated HLA class II molecules is specific for RA synovium.
1
20
T cell cytokines in gut mucosa of patients with spondyloarthropathy reflect immune alterations in Crohn's disease
3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026